How to prevent and treat pharmacological hypoglycemias;Como prevenir y tratar las hipoglucemias farmacológicas

Revista Clinica Espanola

Volumn 214, Issue 4, 2014, Pages 202-208

  Reyes Garcia R ^a,c   Mezquita Raya, P ^b,c  

^a HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Unidad de Endocrinología Nutrición y Riesgo Vascular Complejo Hospitalario Torrecárdenas   (Spain)

^c Servicio de Endocrinología Clínica San Pedro   (Spain)

Author keywords

Antidiabetics; Hipoglycemia; Type 2 diabetes

Indexed keywords

ATORVASTATIN; CYCLOPENTHIAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TELMISARTAN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HYPOCHOLESTEROLEMIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CASE REPORT; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; WEIGHT GAIN; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; PATHOPHYSIOLOGY;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 84899545722     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2013.12.011     Document Type: Article

References (31)

1. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577 1589
2. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
3. A.D. Wright, C.A. Cull, K.M. Mackod, R.R. Holman UKPDS Group Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73 J Diabetes Complic 20 2006 395 401
4. E.R. Seaquist, J. Anderson, B. Childs, P. Cryer, S. Dagogo-Jack, L. Fish American Diabetes Association; Endocrine Society Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society J Clin Endocrinol Metab 98 2013 1845 1859
5. S.R. Heller, P. Choudhary, C. Davies, C. Emery, M.J. Campbell, J. Freeman UK Hypoglycaemia Study Group Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration Diabetologia 50 2007 1140 1147
6. L.A. Donnelly, A.D. Morris, B.M. Frier, J.D. Ellis, P.T. Donnan, R. Durrant DARTS/MEMO Collaboration Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: A population-based study Diabet Med 22 2005 749 755
7. G.P. Leese, J. Wang, J. Broomhall, P. Kelly, A. Marsden, and W. Morrison et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use Diabetes Care 26 2003 1176 1180
8. D. Orozco Beltran, P. Mezquita Raya, A. Ramírez de Arellano, and M. Galán Incidence and frequency of patient-reported hypoglycemic events in Spain Diabetes 62 Suppl 1 2013 A101
9. M. Brito-Sanfiel, J. Diago-Cabezudo, and A. Calderón Economic impact of hypoglycemia on healthcare in Spain Expert Rev Pharmacoecon Outcomes Res 10 2010 649 660
10. L. Lindner, R. García-Sánchez, C. Álvarez, L. Betegón, and X. Badia Hospitalizations due to severe hypoglycemia in patients with diabetes mellitus in Spain Rev Clin Esp 213 2013 370 376
11. R. Gisbert, and M. Brosa Base de Datos de Costes Sanitarios 1997-2004 [CDROM] Versión 1.6 2004 Centro de Estudios en Economía de la Salud y Política Social Barcelona
12. P. Mezquita-Raya, R. Reyes-García, O. Moreno-Pérez, M. Muñoz-Torres, J.F. Merino-Torres, and J.J. Gorgojo-Martínez et al. Documento de posicionamiento: evaluación y manejo de la hipoglucemia en el paciente con Diabetes Mellitus. Grupo de Trabajo de Diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición (SEEN) Endocrinol Nutr 60 2013 517.e1 517.e18
13. E. Menéndez Torre, T. Tarton García, C. Ortega Millán, J.A. Fornos Pérez, R. García Mayr, and M.L. López Fernández Recomendaciones 2012 de la Sociedad Española de Diabetes sobre la utilización de tiras reactivas para la medición de la glucemia capilar en personas con diabetes Av Diabetol 28 2012 3 9
14. W.L. Bennett, L.M. Balfe, and J.M. Faysal AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: A summary of the key findings J Manag Care Pharm 18 1 Suppl A 2012 S1 S20
15. D.S. Shyangdan, P. Royle, C. Clar, P. Sharma, N. Waugh, and A. Snaith Glucagon-like peptide analogues for type 2 diabetes mellitus Cochrane Database Syst Rev 10 2011 CD006423
16. M. Marre, J. Shaw, M. Brändle, W.M. Bebakar, N.A. Kamaruddin, J. Strand LEAD-1 SU study group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabet Med 26 2009 268 278
17. B. Zinman, J. Gerich, J.B. Buse, A. Lewin, S. Schwartz, P. Raskin LEAD-4 Study Investigators Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) Diabetes Care 32 2009 1224 1230
18. D. Russell-Jones, A. Vaag, O. Schmitz, B.K. Sethi, N. Lalic, S. Antic Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial Diabetologia 52 2009 2046 2055
19. T. Ridge, T. Moretto, L. Macconell, R. Pencek, J. Han, and C. Schulteis et al. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonist in patients with type 2 diabetes Diabetes Obes Metab 2012 doi:10.1111/j.1463-1326. 2012.01639.x, [Epub ahead of print]
20. J.B. Buse, M. Nauck, T. Forst, W.H. Sheu, S.K. Shenouda, and C.R. Heilmann et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study Lancet 381 2013 117 124
21. CG87 Type 2 diabetes-newer agents (a partial update of CG66): short guideline [consultado 23 Nov 2013]. Disponible en: http://www.nice.org.uk/ guidance/index.jsp?action=download&o=44318
22. AACE Comprehensive Diabetes Management Algorithm, 2013 [consultado 4 Oct 2013]. Disponible en: http://www.aace.com/publications/algorithm
23. M. Monami, S. Genovese, and E. Mannucci Cardiovascular safety of sulfonylureas: A meta-analysis of randomized clinical trials Diabetes Obes Metab 15 2013 938 953
24. P.C. Butler, M. Elashoff, R. Elashoff, and E.A. Gale A Critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care 36 2013 2118 2125
25. M.A. Nauck A Critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks Diabetes Care 36 2013 2126 2132
26. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/ 2013/07/news-detail-001856.jsp&mid=WC0b01ac058004d5c1 [consultado 23 Nov 2013].
27. http://easd.org/index.php?option=com-content&view=article&id=172 [consultado 23 Nov 2013].
28. M. Evans, K. Khunti, M. Mamdani, C.B. Galbo-Jørgensen, J. Gundgaard, and M. Bøgelund et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: A time trade-off survey in five countries Health Qual Life Outcomes 11 2013 90
29. I.J. Douglas, S.J. Evans, S. Pocock, and L. Smeeth The risk of fractures associated with thiazolidinediones: A self-controlled case-series study PLoS Med 6 2009 e1000154
30. S.C. Liu, Y.K. Tu, M.N. Chien, and K.L. Chien Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: A network meta-analysis Diabetes Obes Metab 14 2012 810 820
31. F. Ismail-Beigi Clinical practice. Glycemic management of type 2 diabetes mellitus N Engl J Med 366 2012 1319 1327